| Artificial Intelligence in Healthcare | Lifetime | 2 | IN 1 | 99.74 |
| Diabetes and associated disorders | Lifetime | 10 | IN 1 | 99.85 |
| Diabetes Management and Education | Lifetime | 6 | IN 1 | 99.86 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 13 | IN 1 | 99.92 |
| Diabetes Management and Research | Lifetime | 25 | IN 1 | 99.83 |
| Liver Disease Diagnosis and Treatment | Lifetime | 102 | IN 3 | 99.81 |
| Chronic Disease Management Strategies | Lifetime | 24 | IN 1 | 99.53 |
| Global Public Health Policies and Epidemiology | Lifetime | 18 | IN 3 | 99.61 |
| Diet, Metabolism, and Disease | Lifetime | 44 | IN 1 | 99.63 |
| Pancreatitis Pathology and Treatment | Lifetime | 51 | IN 1 | 99.59 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 48 | IN 1 | 99.69 |
| Diabetes Treatment and Management | Lifetime | 63 | IN 1 | 99.68 |
| Diet and metabolism studies | Lifetime | 146 | IN 1 | 99.62 |
| Pancreatic function and diabetes | Lifetime | 136 | IN 1 | 99.45 |
| Metabolism, Diabetes, and Cancer | Lifetime | 122 | IN 1 | 99.41 |
| Cardiovascular Health and Risk Factors | Lifetime | 39 | IN 2 | 99.27 |
| Gestational Diabetes Research and Management | Lifetime | 81 | IN 2 | 99.25 |
| Bariatric Surgery and Outcomes | Lifetime | 69 | IN 1 | 98.84 |
| Diabetic Foot Ulcer Assessment and Management | Lifetime | 83 | IN 2 | 98.81 |
| Nutritional Studies and Diet | Lifetime | 218 | IN 1 | 99.16 |
| Retinal Imaging and Analysis | Lifetime | 150 | IN 2 | 99.09 |
| Lipid metabolism and disorders | Lifetime | 84 | IN 2 | 98.70 |
| Cardiovascular Disease and Adiposity | Lifetime | 217 | IN 2 | 98.77 |
| Obesity, Physical Activity, Diet | Lifetime | 400 | IN 2 | 99.00 |
| Natural Antidiabetic Agents Studies | Lifetime | 155 | IN 17 | 98.08 |
| Retinal Diseases and Treatments | Lifetime | 322 | IN 3 | 98.86 |
| Obesity and Health Practices | Lifetime | 123 | IN 1 | 98.46 |
| Lipoproteins and Cardiovascular Health | Lifetime | 348 | IN 2 | 98.50 |
| Biomarkers in Disease Mechanisms | Lifetime | 88 | IN 1 | 96.13 |
| Mobile Health and mHealth Applications | Lifetime | 287 | IN 2 | 97.08 |
| Advanced Glycation End Products research | Lifetime | 265 | IN 9 | 96.33 |
| Cardiovascular Health and Disease Prevention | Lifetime | 653 | IN 4 | 97.23 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 286 | IN 2 | 96.44 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 731 | IN 4 | 95.68 |
| Nutrition, Genetics, and Disease | Lifetime | 705 | IN 2 | 92.98 |
| Chronic Kidney Disease and Diabetes | Lifetime | 978 | IN 7 | 95.13 |
| GABA and Rice Research | Lifetime | 860 | IN 75 | 92.93 |
| Pharmacology and Obesity Treatment | Lifetime | 687 | IN 6 | 93.19 |
| Global Health and Epidemiology | Lifetime | 108 | IN 23 | 89.73 |
| Dietary Effects on Health | Lifetime | 546 | IN 6 | 91.55 |
| Consumer Attitudes and Food Labeling | Lifetime | 745 | IN 2 | 91.58 |
| Food Science and Nutritional Studies | Lifetime | 380 | IN 227 | 84.71 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 896 | IN 10 | 85.76 |
| Skin Diseases and Diabetes | Lifetime | 990 | IN 29 | 79.43 |
| Diabetes Management and Education | 2021-2025 | 2 | IN 1 | 99.75 |
| Diabetes Management and Research | 2021-2025 | 16 | IN 1 | 99.68 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 13 | IN 1 | 99.62 |
| Diet and metabolism studies | 2021-2025 | 49 | IN 1 | 99.17 |
| Diabetes and associated disorders | 2021-2025 | 23 | IN 1 | 98.96 |
| Gestational Diabetes Research and Management | 2021-2025 | 28 | IN 1 | 98.66 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 313 | IN 7 | 98.44 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 59 | IN 1 | 97.99 |
| Diabetes Treatment and Management | 2021-2025 | 134 | IN 1 | 98.51 |
| Bariatric Surgery and Outcomes | 2021-2025 | 58 | IN 1 | 97.30 |
| Pancreatic function and diabetes | 2021-2025 | 119 | IN 1 | 97.49 |
| Diet, Metabolism, and Disease | 2021-2025 | 87 | IN 1 | 97.34 |
| Nutritional Studies and Diet | 2021-2025 | 237 | IN 1 | 96.64 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 157 | IN 14 | 92.06 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 151 | IN 2 | 93.21 |
| Chronic Disease Management Strategies | 2021-2025 | 296 | IN 9 | 92.31 |
| COVID-19 and healthcare impacts | 2021-2025 | 913 | IN 16 | 89.20 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 93 | IN 1 | 90.23 |
| Birth, Development, and Health | 2021-2025 | 707 | IN 8 | 91.56 |
| Artificial Intelligence in Healthcare | 2021-2025 | 270 | IN 96 | 90.47 |
| Pregnancy and preeclampsia studies | 2021-2025 | 741 | IN 5 | 91.41 |
| Mobile Health and mHealth Applications | 2021-2025 | 466 | IN 4 | 89.48 |
| Retinal Imaging and Analysis | 2021-2025 | 629 | IN 31 | 91.25 |
| Retinal Diseases and Treatments | 2021-2025 | 998 | IN 31 | 91.31 |
| Nutrition, Genetics, and Disease | 2021-2025 | 535 | IN 1 | 75.48 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 241 | IN 6 | 72.09 |
| Regulation of Appetite and Obesity | 2021-2025 | 840 | IN 6 | 66.95 |
| Food Science and Nutritional Studies | 2021-2025 | 270 | IN 132 | 58.66 |
